PLOD2 and glioblastoma: Furthermore, the Kaplan-Meier estimates based on the TCGA dataset showed significant differences in overall survival (OS) and progression free survival (PFS) between glioblastoma patients with low PLOD2 expression and those with high expression (Figure 1F, P < 0.05; Figure 1G, P < 0.0005, by the log-rank test).